Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2200 • ACR Convergence 2022
Reliability of Medication Information Derived from EHR Data Compared to Insurance Claims: An Analysis of Biologic Medications in RISE and Medicare
Rahaf Baker¹, Jing Li², Rachael Stovall³, Jeffrey Curtis⁴, Fenglong Xie⁵, Jinoos Yazdany⁶ and Gabriela Schmajuk⁷, ¹Alameda Highland Internal Medicine Residency, Oakland, CA, ²University of California, San Francisco, San Francisco, CA, ³University of California San Francisco, San Francisco, CA, ⁴University of Alabama at Birmingham, Hoover, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶UCSF, San Francisco, CA, ⁷UCSF / SFVA, San Francisco, CA
Background/Purpose: Health services studies increasingly rely on Electronic Health Record (EHR) data to capture medication use. However, the reliability of medication information derived from EHR…
Abstract Number: 2262 • ACR Convergence 2022
Albumin-hitchhiking MMP13 siRNA Conjugate (siMMP13< (EG18L)2) for the Treatment of Rheumatic Disease
Juan Colazo¹, Ella Hoogenboezem¹, Fang Yu¹, Veeraj Shah¹, Justin Lo¹, Hongsik Cho², Karen Hasty², Leslie Crofford³ and Craig Duvall¹, ¹Department of Biomedical Engineering, Vanderbilt University, Nashville, Nashville, TN, ²Department of Orthopaedic Surgery and Biomedical Engineering, Memphis VA Medical Center, Memphis, TN, ³Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Osteoarthritis (OA) and rheumatoid arthritis (RA) decrease quality of life due to joint destruction, pain, and decreased function. Multiple joint osteoarthritis (MJOA) can occur…
Abstract Number: 0069 • ACR Convergence 2022
Capturing Clinical Reasoning in Real Time Reveals Low Rate of Serious Adverse Reactions Requiring B/tsDMARD Discontinuation in Inflammatory Joint Disease: An Analysis of the OPAL Real-World Dataset
Geoffrey Littlejohn¹, Tegan Smith², Sabina Ciciriello³, Peter Youssef⁴, Claire Deakin⁵, Nithila Anbumurali⁶ and Catherine OSullivan⁶, ¹OPAL Rheumatology Ltd, Melbourne, Australia, ²OPAL Rheumatology Ltd, Geelong, Australia, ³Melbourne Health, Melbourne, Australia, ⁴University of Sydney, Sydney, Australia, ⁵OPAL Rheumatology Ltd, Mosman, Australia, ⁶OPAL Rheumatology Ltd, Sydney, Australia
Background/Purpose: Routine management of inflammatory joint disease requires clinicians to consider an abundance of factors unique to each patient when deciding on the most appropriate…
Abstract Number: 0181 • ACR Convergence 2022
Patient Perspective of Unique Support and Education Needs of Latinx/Latino(a)/Hispanic Rheumatoid Arthritis Patients: Implications for a Culturally Tailored and Disease Specific Intervention
Anna Balakrishnan¹, Adena Batterman¹, Daniel Hernandez², Angel Tapia³, Joan Westreich¹, Roberta Horton¹ and Theodore Fields¹, ¹Hospital for Special Surgery, New York, NY, ²Global Healthy Living Foundation, Nyack, NY, ³Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose: Health disparities for Latinx RA patients, including higher pain, fatigue, disability, and risk for depression are well documented.1, 2, 3, 4 Support and education…
Abstract Number: 0246 • ACR Convergence 2022
Comorbidity Clusters in Patients with Rheumatoid Arthritis Predict Survival Prognosis
Cynthia Crowson¹, Tina Gunderson², John Davis², Elena Myasoedova², Vanessa Kronzer², Caitrin Coffey², Bradly Kimbrough³ and Elizabeth Atkinson², ¹Mayo Clinic, Eyota, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic Rochester, Rochester, MN
Background/Purpose: Comorbidities are common in patients with rheumatoid arthritis (RA), but there is little information regarding the occurrence of distinct comorbidity patterns in patients with…
Abstract Number: 0262 • ACR Convergence 2022
Predictors of Fragility Fracture Amongst Patients with Rheumatoid Arthritis: An Observational Cohort Study
Seema Sharma¹ and Marwan Bukhari², ¹Lancaster Royal Infirmary, Lancaster, United Kingdom, ²University Hospitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is associated with reduced bone mineral density and almost one third of this population have osteoporosis leading to increased risk of…
Abstract Number: 0279 • ACR Convergence 2022
Effect of Filgotinib on Body Weight and BMI and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in RA
Alejandro Balsa¹, Siegfried Wassenberg², Anne Tournadre³, Hans-Dieter Orzechowski⁴, Katrien Van Beneden⁵, Vijay Rajendran⁶, Udo Lendl⁴, Pieter-Jan Stiers⁵, Christopher Watson⁷, Roberto Felice Caporali⁸ and Patrick Verschueren⁹, ¹Hospital La Paz Institute for Health Research, Madrid, Spain, ²Rheumazentrum Ratingen, Ratingen, Germany, ³University Hospital of Clermont Ferrand, Rheumatology, Clermont-Ferrand, France, ⁴Galapagos Biopharma Deutschland GmbH, Munich, Germany, ⁵Galapagos NV, Mechelen, Belgium, ⁶Galapagos NV, Gent, Belgium, ⁷Galapagos Biotech Ltd, Cambridge, United Kingdom, ⁸University of Milan, Milano, Italy, ⁹University Hospital Leuven, Leuven, Belgium
Background/Purpose: Filgotinib (FIL) is a Janus kinase (JAK) 1 preferential inhibitor approved for the treatment (tx) of moderate to severe RA. Weight gain has been…
Abstract Number: 0296 • ACR Convergence 2022
Characteristics and Treatment-selection in Patients with Rheumatoid Arthritis and with Inadequate Response to Janus Kinase Inhibitors
Yusuke Miyazaki¹, Shingo Nakayamada², Satoshi Kubo³, Koshiro Sonomoto², Yoshino Inoue², shunsuke fukuyo², Kentaro Hanami² and Yoshiya Tanaka⁴, ¹The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kiakyusyu Fukuoka, Japan, ²First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ³Department of Advanced Targeted Therapies, University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁴University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan
Background/Purpose: Janus kinase inhibitors (JAKinib) are effective in patients with rheumatoid arthritis (RA); however, some patients show an inadequate response to JAKinibs (JAKinib-IR). This study…
Abstract Number: 0314 • ACR Convergence 2022
Olokizumab Improved Patient Reported Outcomes in TNF Incomplete Responder (TNF-IR) Rheumatoid Arthritis Patients: Results from the Phase III Randomized Controlled Trial
Vibeke Strand¹, Evgeny Nasonov², Tatiana Lisitsyna², Alexander Lila², Sofia Kuzkina³, Mikhail Samsonov⁴ and Eugen Feist⁵, ¹Stanford University School of Medicine, Stanford, CA, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ³R-Pharm, Moscow, Russia, ⁴R-Pharm JSC, Moscow, Russia, ⁵Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany
Background/Purpose: Olokizumab (OKZ) is an interleukin-6-inhibitor for treatment of rheumatoid arthritis (RA). In these analyses we present patient reported outcomes (PROs) reported by TNF-IR patients…
Abstract Number: 0549 • ACR Convergence 2022
Efficacy and Safety of the SARS-CoV-2 Vaccine in Patients with Rheumatoid Arthritis
Esther Vicente-Rabaneda¹, María Torres², Miren Uriarte³, Patricia Quiroga-Colina³, Ainhoa Gutiérrez⁴, Ana Triguero⁵, Francisco Gutiérrez³, Noelia García³, Ana Romero-Robles³, Laura Cardeñoso⁴ and Santos Castañeda¹, ¹Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ²Medical student, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁴Division of Microbiology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Hospital Universitario La Princesa, Madrid, Spain
Background/Purpose: To describe the efficacy and safety of the SARS-CoV-2 vaccine in a series of patients with rheumatoid arthritis (RA).Methods: Retrospective observational study of RA…
Abstract Number: 0594 • ACR Convergence 2022
Identification of Peptidylglycine Alpha-Amidating Monooxygenase as a Regulator of Tissue Damage Mediated by Rheumatoid Arthritis Synovial Fibroblasts
Kevin Sheridan¹, Emma Dorris¹, Christopher Buckley² and Anthony Wilson¹, ¹University College Dublin, Dublin, Ireland, ²University of Oxford, Oxford, United Kingdom
Background/Purpose: The minor C allele variant of rs26232 SNP, located within the first intron of the Macrophage Immunometabolism regulator (MACIR) gene, is associated with both…
Abstract Number: 0611 • ACR Convergence 2022
Proteomics Reveals Dysregulated Molecular Mechanisms of Cell Death in Neutrophils in Rheumatoid Arthritis
Jennifer Amsler¹, Constance Beaudouin², Morgane LeGall³, Géraldine Falgarone⁴, François Rannou⁵, Léa Tourneur³ and Véronique Witko-Sarsat³, ¹Institute Cochin, Schoenenwerd, Switzerland, ²Hôpital Privé de Provence, Aix-en-Provence, France, ³Institute Cochin, Paris, France, ⁴Hôpital Avicenne, Paris, France, ⁵Hôpital Cochin, Paris, France
Background/Purpose: Favoring apoptosis of neutrophils infiltrating the joints of patients suffering from rheumatoid arthritis (RA) and perpetuating inflammation has recently been discussed as an alternative…
Abstract Number: 0628 • ACR Convergence 2022
A Positive-feedback Model for the Contribution of Virus-Specific T Cells to the Development of Rheumatoid Arthritis
Hendrik Nel¹, Pascale Wehr², Christopher Andoniou³, Iona Schuster³, Stephanie Gras⁴, Helen McGuire⁵, Helen Weedon⁶, Annabelle Small⁷, Katie Lowe⁷, Mariapia Degli-Esposti³, Mihir Wechalekar⁸ and Ranjeny Thomas⁹, ¹University of Queensland, Brisbane, Australia, Woolloongabba, Australia, ²University of Queensland Diamantina Institute, Brisbane, Australia, ³Infection and Immunity Program and Department of Microbiology, Biomedicine Discovery Institute, Monash, Australia, ⁴Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia, ⁵The University of Sydney, Charles Perkins Centre, Camperdown, Australia, ⁶Flinders University of South Australia, Bedford Park, Australia, ⁷Flinders University, Adelaide, Australia, ⁸Flinders Medical Centre, Bedford Park, Australia, ⁹University of Queensland, Brisbane, Australia
Background/Purpose: Rheumatoid Arthritis (RA) is associated with specific HLA-DR genotypes with an emphasis on the role of CD4+ effector-memory T cells (Tem) in disease pathogenesis.…
Abstract Number: 0763 • ACR Convergence 2022
Immunogenicity Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis
Vibeke Strand¹, Shaun Bender² and Dorothy McCabe³, ¹Stanford University School of Medicine, Stanford, CA, ²Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, ³Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT
Background/Purpose: The VOLTAIRE trials program compared the safety, efficacy, and immunogenicity of biosimilar BI 695501 with adalimumab reference product (RP) for indications including moderate-severely active…
Abstract Number: 0884 • ACR Convergence 2022
Serum Calprotectin Can Differentiate Between Sustained Remission and Low Disease Activity States in Rheumatoid Arthritis
Margaret Ma¹, Fowzia Ibrahim², David Scott² and Andrew Cope³, ¹National University Hospital, Singapore, Singapore, ²King's College London, London, United Kingdom, ³King's College London, Surrey, United Kingdom
Background/Purpose: Reliable objective assessment of remission is important for the optimal management of rheumatoid arthritis (RA) patients. Calprotectin is a heterocomplex of the S100 proteins…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].